Full Text
Full text is available in PDF
Treatment of Advanced Transitional Cell Carcinoma of the Bladder by Irinotecan in an Experimental Animal Model
Authors
1Departement of Urology, University Clinic, Krankenhaustr. 12, 91054, Germany
2Departement of Urology, University Clinic, Krankenhaustr. 12, 91054, steffen.krause@uk-erlangen.de, Germany
*Corresponding Author: Departement of Urology, University Clinic, Krankenhaustr. 12, 91054, steffen.krause@uk-erlangen.de, Germany. Tel: +49/9131/822-3868. Fax: +49/9131/822-3179. Email: steffen.krause@uk-erlangen.de
Published online:Jul 31, 2010
Article type:Research Article
Received:Oct 08, 2009
Accepted:Nov 27, 2009
Abstract
Background and Aims:
In advanced transitional cell cancer of the bladder a systemic chemotherapy isconsidered therapy of choice with palliative intent in spite of an unsatisfactory rate of remission. We tested a new chemotherapeutic agent, irinotecan, presenting with fair response rates in patients with advanced intestinal carcinomas, in animals with poorly differentiated transitional cell carcinomas (TCC).
Methods:
The effect of irinotecan was tested using single and multiple applications as well as in combination with docetaxel. Local tumor growth and body weight of mice were registered frequently. Histopathology of local tumor and previously defined organs were obtained after death. All data were proofed statistically.
Results:
The animal groups are statistically significant different for the tumor size (p < 0.01). Post-hoc tests showed that the control group and the irinotecan monotherapy (p = 0.04), as well as the irinotecan/docetaxel group (p < 0.01) are significant different for a reduced tumor mass. No significance could be detected for regression rate and survival time of the animals.
Conclusions:
The chemotherapy of irinotecan as monotherapy or in combination with docetaxel seems to be a promising alternative in the palliative treatment of advanced, metastatic transitional cell cancer of the bladder. Due to the significant influence of irinotecan on the reduction of tumor mass, we are planning a prospective randomised study to confirm these data in humans.
Highlights
How to Cite:Landsmann S, Schwarz S, Papadopoulos T, Haeberle L, Engehausen D, et al. Treatment of Advanced Transitional Cell Carcinoma of the Bladder by Irinotecan in an Experimental Animal Model. Nephro-Urol Mon. 2010;2(3):. doi:
Copyright
© 2010, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
30
Sep
2013
![The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine](https://brieflands.com/journals/ijcm/articles/80420/figures/thumbnail.webp)
The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine
Seyyed-Hossein Yahyazadeh-Jabbari,
Nasser Malekpour,
Bahram Salmanian,
Hossein Foodazi,
Masoud Salehi,
Farsad Noorizadeh
Yahyazadeh-Jabbari S, Malekpour N, Salmanian B, Foodazi H, Salehi M, et al. The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine. Int J Cancer Manag. 2013;6(3):e80420. doi:
16
Jan
2016
Improving Compliance With a Single Post-Operative Dose of Intravesical Chemotherapy After Transurethral Resection of Bladder Tumour
Luke Stroman,
Ben Tschobotko,
Hamid Abboudi,
David Ellis,
Elsie Mensah,
Harikesh Kaneshayogan
,et al.Stroman L, Tschobotko B, Abboudi H, Ellis D, Mensah E, et al. Improving Compliance With a Single Post-Operative Dose of Intravesical Chemotherapy After Transurethral Resection of Bladder Tumour. Nephro-Urol Mon. 2016;8(1):e29967. doi: https://doi.org/10.5812/numonthly.29967
31
Jan
2020
A Preliminary Study of NER and MMR Pathways Involved in Chemotherapy Response in Bladder Transitional Cell Carcinoma: Impact on progression-free survival
Vahideh Montazeri,
Mohammad Hossein Ghahremani,
Hamed Montazeri,
Mandana Hasanzad,
d, Majid Safavi,
Mohsen Ayati
,et al.Montazeri V, Ghahremani MH, Montazeri H, Hasanzad M, Safavi DM, et al. A Preliminary Study of NER and MMR Pathways Involved in Chemotherapy Response in Bladder Transitional Cell Carcinoma: Impact on progression-free survival. Iran J Pharm Res. 2020;19(1):e124447. doi: https://doi.org/10.22037/ijpr.2020.112646.13878
17
May
2021
Comparison of Re-TUR Results in Primary Patients with Non-muscle-Invasive Bladder Cancer (NMIBC) of Low, Intermediate, and High-risk for Recurrence Based on the EORTC Scoring System
Farhood Khaleghi Mehr,
Pejman Shadpour,
Hossein Shahrokh,
Nima Narimani,
Maryam Abolhasani,
Mohsen Shati
Khaleghi Mehr F, Shadpour P, Shahrokh H, Narimani N, Abolhasani M, et al. Comparison of Re-TUR Results in Primary Patients with Non-muscle-Invasive Bladder Cancer (NMIBC) of Low, Intermediate, and High-risk for Recurrence Based on the EORTC Scoring System. Nephro-Urol Mon. 2021;13(2):e99800. doi: https://doi.org/10.5812/numonthly.99800
30
Apr
2017
Comparative Study Between Two Treatment Regimens of Cisplatin-5-Fluorouracil and Gemcitabine-Cisplatin in Gallbladder Cancer Patients
Daud Ali,
Nawazish Alam,
Farhat Yasmin,
Sajid Ali,
Tarique Anwer,
Sarfaraz Alam
,et al.Ali D, Alam N, Yasmin F, Ali S, Anwer T, et al. Comparative Study Between Two Treatment Regimens of Cisplatin-5-Fluorouracil and Gemcitabine-Cisplatin in Gallbladder Cancer Patients. Iran J Pharm Res. 2017;16(2):e125015. doi: https://doi.org/10.22037/ijpr.2017.2038
Cited by
- Scopus by DOI: 0
Last Update: 3 days ago
- Scopus by Title: 0
Last Update: 3 days ago
- Scopus by Title (Ref): 0
Last Update: 3 days ago
- CrossRef: 0
Last Update: 4 days ago
- OpenAlex: 0
Last Update: 2 days ago
- OpenCitations: 0
Last Update: 1 day ago
Comments
Number of Comments:0Indexed in
